Seeking Alpha

Momenta Pharmaceuticals (MNTA -19%) gets slammed today after this weekend's unfavorable ruling...

Momenta Pharmaceuticals (MNTA -19%) gets slammed today after this weekend's unfavorable ruling against the company in the Copaxone patent litigation brought against the company by Teva (TEVA +5.6%). Oppenheimer says the stock still has compelling long-term value , despite pressure over the near-term.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|